CLIMB Study V1.0
Research type
Research Study
Full title
Immune Checkpoint Inhibitor Effects on Lung Airway Mutational Burden
IRAS ID
295888
Contact name
Samuel Janes
Contact email
Sponsor organisation
UCLH/UCL Joint Research Office (part of the Research Directorate)
Duration of Study in the UK
5 years, 4 months, 31 days
Research summary
Lung cancer develops from cells which have developed abnormal genetic patterns. We know that new lung cancer treatments called immunotherapy are able to recognise and kill abnormal cancer cells, but no one has tested whether immunotherapy affects cells which are abnormal but not yet cancerous. This study aims to investigate how immunotherapy affects healthy-looking cells that have abnormal genetics,
To do this, we would like to collect normal-looking lung cells from people before and after they receive immunotherapy, to see whether the immunotherapy treatment affects the number of cells with pre-canerous genetic changes. By doing this research, we will be able to to see whether immunotherapy could be used in to reduce the number of high-risk cells before they turn into a cancer.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
22/NW/0397
Date of REC Opinion
24 Jan 2023
REC opinion
Further Information Favourable Opinion